Evidence map›Paper›PMID 31253494›Full record

ArticleParkinsonism & related disorders2019

Measuring quality of life in palliative care for Parkinson's disease: A clinimetric comparison.

Samantha K Holden, Claire E Koljack, Lindsay P Prizer, Stefan H Sillau, Janis M Miyasaki, Benzi M Kluger

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Parkinsonism & related disorders, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Palliative Care for Parkinson's Spectrum Disorders: an Emerging Approach.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2020
    Review
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Samantha K HoldenDepartment of Neurology, University of Colorado School of Medicine, Aurora, CO, USA. Electronic address: samantha.holden@ucdenver.edu.
Claire E KoljackDepartment of Neurology, University of Colorado School of Medicine, Aurora, CO, USA.
Lindsay P PrizerDepartment of Medicine, Emory University, Atlanta, GA, USA.
Stefan H SillauDepartment of Neurology, University of Colorado School of Medicine, Aurora, CO, USA.
Janis M MiyasakiDepartment of Medicine, Division of Neurology, University of Alberta, Edmonton, Canada.
Benzi M KlugerDepartment of Neurology, University of Colorado School of Medicine, Aurora, CO, USA.

Funding

NINDS NIH HHS L30 NS103315Patient-Centered Outcomes Research Institute IHS-1408-20134
6 · The paper itself

Abstract

introductionQuality of life (QOL) assessments allow for more complete evaluation of patients' lived experiences in relation to chronic conditions, such as Parkinson's disease (PD). In palliative care, such instruments are vital to ensure QOL issues are catalogued and addressed for patients. However, little is known regarding the psychometric properties of quality of life scales for use in palliative care for PD, specifically.

methods210 participants with parkinsonian disorders, who participated in a larger palliative intervention clinical trial, completed four quality of life scales (PDQ-39, PROMIS-29, QOL-AD, and McGill QOL) at baseline and post-intervention. Psychometric properties, including internal consistency and concurrent validity, were examined. Factor analyses were performed to evaluate relationships between scale items. Minimal clinically important differences (MCID) and responsiveness were calculated for each scale.

resultsAll scales demonstrated good internal consistency and concurrent validity. Factor analyses revealed few deviations from the defined subdomains of the scales. Mean absolute MCID values were estimated at 12.7, 10.9, 3.9, and 18.9 for PDQ-39, PROMIS-29, QOL-AD, and McGill QOL, respectively. The PDQ-39 and PROMIS-29 demonstrated higher responsiveness to palliative intervention, while the QOL-AD was more responsive in the control group.

conclusionsThe PDQ-39, PROMIS-29, QOL-AD, and McGill QOL are all valid for use in PD palliative care, though subdomains of the scales in this population may differ slightly from those initially defined. We recommend the use of PDQ-39 and PROMIS-29 as outcome measures in clinical trials for palliative care in PD, though the QOL-AD may be superior for tracking disease progression.

Indexed as

Disease ProgressionPalliative CareQuality of LifeAgedAged, 80 and overFemaleHumansLewy Body DiseaseMaleMiddle AgedMultiple System AtrophyOutcome Assessment, Health CareParkinson DiseaseParkinsonian DisordersPatient Outcome AssessmentPsychometricsOutcome measuresPalliative careParkinson diseasePsychometricsQuality of life

Identifiers

PMID31253494
PMCPMC6774894

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.